FDA+ channel feed – Endpoints News

FDA+ channel feed

FDA rejects liver cancer drug combo, shares of Korean biotech tank

11 months ago

Q&A: FTC’s top healthcare enforcer on pharma M&A, company growth and PBMs

11 months ago

FDA approves Amgen’s T cell engager in aggressive form of lung cancer

11 months ago

House panel advances bills targeting rare disease, priority review vouchers

11 months ago

Bristol Myers' CAR-T therapy Breyanzi adds follicular lymphoma to list of approvals

11 months ago

WHO greenlights Takeda's dengue vaccine as company plans to 're-engage' with FDA

11 months ago

As adcomm looms, ICER raises questions over Lykos’ MDMA studies

11 months ago

Eisai heads to FDA with subcutaneous version of Alzheimer’s treatment developed with Biogen

12 months ago

Ascendis’ hypoparathyroidism drug saddled with three-month delay at FDA

12 months ago

Destruction of documents, insufficient data lead FDA to reject hep B vaccine update

12 months ago

FDA offers more clarity on safety testing for cell therapies

12 months ago

WHO members miss deadline for pandemic accord draft, will continue talks

12 months ago

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

12 months ago

Senators question Chamber of Commerce's motives around march-in rights

12 months ago

Corrected: Experts to decide within a year whether to recommend Duchenne muscular dystrophy for newborn screening

Last year

Ahead of likely approval, ICER finds Geron’s imetelstat is not cost-effective at $250,000 annually

Last year

House panel marks up bill to require PBMs to use a flat fee in Medicare

Last year

Senate appropriators question FDA commissioner on H5N1 virus prep

Last year

White House unveils long-awaited policy on overseeing research of concern

Last year

House Oversight chair presses FDA on China amid growing tensions

Last year

Lilly gets June adcomm for Alzheimer's drug donanemab, following earlier delay

Last year

Sen. Cassidy calls on Biden to do better at sharing H5N1 bird flu information

Last year

Industry groups critique new guidance for Medicare drug price negotiations in 2027

Last year

Remodeling REMS: FDA kicks off guidance series with draft on new framework

Last year

First page Previous page 23 24 252627 28 29 Next page Last page